Time Trends in the Treatment and Survival of 5036 Uveal Melanoma Patients in The Netherlands over a 30-Year Period.
primary tumor
survival
time trends
treatment
uveal melanoma
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
15 Nov 2023
15 Nov 2023
Historique:
received:
19
10
2023
revised:
08
11
2023
accepted:
13
11
2023
medline:
25
11
2023
pubmed:
25
11
2023
entrez:
25
11
2023
Statut:
epublish
Résumé
Uveal melanoma (UM) is a rare intraocular tumor with a dismal prognosis once metastasized. This study provides a nationwide overview and time trends of patients diagnosed with primary UM in the Netherlands between 1989 and 2019. A retrospective population-based cohort study based on patients with primary UM from the database of the Netherlands Cancer Registry (NCR), linked with the national population registry Statistics Netherlands on inhabitants' cause of death. Two time periods (1989-2004, 2005-2019) were compared with descriptive statistics. Kaplan-Meier and (multivariate) Cox proportional hazard models were used to assess changes over time for overall survival (OS) and cancer-specific survival (CSS). In total, 5036 patients were analyzed with a median age of 64.0 years at the time of diagnosis. The number of patients increased over time. In the first (1989-2004) and second (2005-2019) period, 32% versus 54% of the patients received radiotherapy ( In this study of patients with primary UM, there was a shift to the diagnosis of smaller tumors, possibly due to stage migration. There was also an increase in eye-preserving treatments over time. OS and CSS were modestly improved in the second time period; however, the time period was not associated with OS or CSS in multivariate analyses.
Sections du résumé
BACKGROUND
BACKGROUND
Uveal melanoma (UM) is a rare intraocular tumor with a dismal prognosis once metastasized. This study provides a nationwide overview and time trends of patients diagnosed with primary UM in the Netherlands between 1989 and 2019.
METHODS
METHODS
A retrospective population-based cohort study based on patients with primary UM from the database of the Netherlands Cancer Registry (NCR), linked with the national population registry Statistics Netherlands on inhabitants' cause of death. Two time periods (1989-2004, 2005-2019) were compared with descriptive statistics. Kaplan-Meier and (multivariate) Cox proportional hazard models were used to assess changes over time for overall survival (OS) and cancer-specific survival (CSS).
RESULTS
RESULTS
In total, 5036 patients were analyzed with a median age of 64.0 years at the time of diagnosis. The number of patients increased over time. In the first (1989-2004) and second (2005-2019) period, 32% versus 54% of the patients received radiotherapy (
CONCLUSIONS
CONCLUSIONS
In this study of patients with primary UM, there was a shift to the diagnosis of smaller tumors, possibly due to stage migration. There was also an increase in eye-preserving treatments over time. OS and CSS were modestly improved in the second time period; however, the time period was not associated with OS or CSS in multivariate analyses.
Identifiants
pubmed: 38001679
pii: cancers15225419
doi: 10.3390/cancers15225419
pmc: PMC10670516
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Ann Surg Oncol. 2021 Feb;28(2):1130-1141
pubmed: 32761328
Control Clin Trials. 1996 Aug;17(4):343-6
pubmed: 8889347
Commun Med (Lond). 2022 Mar 1;2:18
pubmed: 35603296
Melanoma Res. 2022 Apr 1;32(2):103-111
pubmed: 35254333
J Clin Oncol. 2018 Apr 20;36(12):1232-1239
pubmed: 29528792
Cancer. 2003 Jan 15;97(2):465-75
pubmed: 12518371
J Clin Oncol. 2005 Nov 1;23(31):8076-80
pubmed: 16258106
Br J Ophthalmol. 2023 Mar;107(3):406-411
pubmed: 34880052
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
N Engl J Med. 1985 Jun 20;312(25):1604-8
pubmed: 4000199
J Clin Oncol. 2021 Feb 20;39(6):599-607
pubmed: 33125309
Arch Ophthalmol. 2002 Dec;120(12):1665-71
pubmed: 12470140
Cancers (Basel). 2019 Oct 03;11(10):
pubmed: 31623302
Ophthalmology. 2011 Sep;118(9):1881-5
pubmed: 21704381
Mol Cancer Ther. 2020 Apr;19(4):1031-1039
pubmed: 32029634
J Contemp Brachytherapy. 2019 Dec;11(6):554-562
pubmed: 31969914
Ophthalmology. 2007 Dec;114(12):2309-15
pubmed: 17498805
Ophthalmology. 2016 Apr;123(4):898-907
pubmed: 26854035
Cancer Chemother Pharmacol. 2019 Jul;84(1):15-32
pubmed: 31079217
Cardiovasc Intervent Radiol. 2022 Sep;45(9):1304-1313
pubmed: 35922562
Arch Ophthalmol. 2005 Dec;123(12):1639-43
pubmed: 16344433
Expert Rev Anticancer Ther. 2006 Apr;6(4):493-506
pubmed: 16613538
Ocul Oncol Pathol. 2018 Apr;4(3):145-151
pubmed: 29765944
Ophthalmology. 2022 Apr;129(4):431-437
pubmed: 34793831
Melanoma Res. 2019 Dec;29(6):561-568
pubmed: 30664106
HPB (Oxford). 2020 Apr;22(4):497-505
pubmed: 31791894
J Clin Oncol. 2021 Feb 20;39(6):586-598
pubmed: 33417511
Med Clin North Am. 2021 May;105(3):531-550
pubmed: 33926645
Eur J Cancer. 2016 Nov;68:106-113
pubmed: 27741435
Eye (Lond). 2017 Feb;31(2):241-257
pubmed: 27911450
Semin Intervent Radiol. 2020 Dec;37(5):508-517
pubmed: 33328707
Trials. 2022 Feb 13;23(1):137
pubmed: 35152908
Cancer Immunol Immunother. 2022 Jun;71(6):1467-1477
pubmed: 34709438
Nat Rev Dis Primers. 2020 Apr 9;6(1):24
pubmed: 32273508
N Engl J Med. 2021 Sep 23;385(13):1196-1206
pubmed: 34551229
Ann Oncol. 2019 Aug 1;30(8):1370-1380
pubmed: 31150059
Ocul Oncol Pathol. 2021 Mar;7(2):133-141
pubmed: 33981696
Cancer Treat Rev. 2023 Feb;113:102501
pubmed: 36587472
Expert Rev Anticancer Ther. 2022 Oct;22(10):1017-1027
pubmed: 36102132
Ann Surg Oncol. 2016 Apr;23(4):1309-19
pubmed: 26597368
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32581057
Br J Cancer. 2010 Jul 27;103(3):285-90
pubmed: 20661247
Invest Ophthalmol Vis Sci. 2003 Nov;44(11):4651-9
pubmed: 14578381
Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1218-24
pubmed: 23177670
J Immunother Cancer. 2019 Nov 13;7(1):299
pubmed: 31722735
Curr Opin Ophthalmol. 2022 Nov 1;33(6):585-590
pubmed: 36094043